An abnormal Saint Louis University Mental Status (SLUMS) exam result calls for a full cognitive evaluation, not an automatic dementia diagnosis. Next steps usually include reviewing symptoms and daily function, checking for other causes, ordering laboratory tests, and obtaining brain imaging. SLUMS is a brief cognitive screening tool. Saint Louis University states that a qualified professional must interpret it as part of a complete assessment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Was the screening result reliable?
- What happens during the full evaluation?
- Which medical tests may follow?
- Why might the clinician order brain imaging?
- When are specialist biomarker tests appropriate?
Was the screening result reliable?
SLUMS is intended to detect cognitive change in adults age 60 or older. A clinician should consider whether testing conditions affected the result before drawing conclusions. Potential problems include nonstandard administration, uncorrected hearing or vision impairment, and limited English proficiency without an appropriate translation.
Traumatic brain injury can also compromise the test's validity. Tell the clinician if the person could not hear instructions, struggled to see the test, needed another language, or has a history of brain injury. These details may change how much weight the score receives.
What happens during the full evaluation?
The clinician interviews the person and, when possible, someone familiar with their everyday behavior. The evaluation covers symptoms, health history, medicines, behavior, and the ability to handle daily activities. cognitive testing examines thinking skills in more depth.
A psychiatric assessment may also help distinguish dementia from depression or another contributor. The National Institute on Aging describes this combined assessment as part of diagnosing Alzheimer's disease and other causes of cognitive symptoms. Prepare for the appointment by bringing:.
- A complete list of prescription medicines, over-the-counter products, and supplements
- Notes about when cognitive or behavioral changes began
- Examples of changes in everyday activities
- A relative or friend who has observed the changes
- Information about sleep, mood, sensory problems, strokes, or other health changes
Which medical tests may follow?
Blood, urine, or other medical tests help identify conditions that can cause or worsen cognitive problems. Possible contributors include infection, medication effects, sleep problems, depression, stroke, and other medical conditions. Some are treatable.
For someone with an established cognitive-behavioral syndrome, the Alzheimer's Association guideline recommends a first-tier laboratory panel. It includes thyroid-stimulating hormone, vitamin B12, a complete blood count, metabolic testing, and the inflammatory markers ESR and CRP. An abnormal screening score alone does not justify ordering every available test. Additional tests should reflect the person's symptoms, medical history, and specific risks.
Why might the clinician order brain imaging?
Structural brain imaging helps clinicians assess brain changes and look for another explanation. It may reveal atrophy or findings such as stroke, bleeding, excess fluid known as hydrocephalus, or a mass. The Alzheimer's Association DETeCD-ADRD guideline recommends MRI without contrast when possible.
A noncontrast CT scan is the usual alternative when MRI is unavailable or cannot be performed. Imaging adds evidence, but it does not replace the history, functional assessment, cognitive examination, and medical testing. Clinicians interpret those findings together.
When are specialist biomarker tests appropriate?
If the cause remains uncertain after clinical assessment and structural imaging, a dementia specialist may consider advanced testing. Options include FDG-PET, cerebrospinal-fluid testing for amyloid and tau, or amyloid PET. Amyloid or tau PET is not a routine response to one abnormal SLUMS score.
Updated Alzheimer's Association criteria say these scans should be ordered when the result will directly affect care, such as clarifying the cause or determining treatment eligibility. Blood-based Alzheimer's biomarkers also are not a stand-alone next step. The Alzheimer's Association's 2025 specialty-care guidance limits their use to people with objective cognitive impairment after a comprehensive evaluation. It also warns that many commercially available tests do not meet recommended accuracy thresholds.
